Dulaglutide is cardioprotective with or without background metformin in patients with diabetes and established or high risk for coronary vascular disease. A subgroup analysis of the REWIND Trial
暂无分享,去创建一个
G. Dagenais | R. Diaz | J. Probstfield | M. Riddle | L. Rydén | H. Colhoun | M. Lakshmanan | L. Dyal | L. Mellbin | G. Ferrannini | H. Gerstein | J. Shaw